Search Results

AbbVie is joining the amylin arena, though the pharma is still far behind leaders Novo Nordisk and Eli Lilly.

Amylin analogs present a strong alternative or complement to GLP-1 receptor agonists, potentially eliciting higher-quality weight loss with a cleaner tolerability profile.

Roche and Zealand plan to study petrelintide as a monotherapy and in combination with CT-388, a dual agonist of the GLP-1 and GIP receptors that Roche picked up in its recent acquisition of Carmot Therapeutics.

Viking Therapeutics, Inc. today announced the presentation of preclinical data from a series of internally developed dual agonists of the amylin and calcitonin receptors at the 84th Scientific Sessions of the American Diabetes Association.

Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide

Sciwind Biosciences Co., Ltd. announced that the company will present positive results from a Phase 3 clinical study of injectable ecnoglutide in T2DM patients and from a Phase 1 study for oral ecnoglutide in healthy and healthy obese participants, as well as preclinical data for novel amylin analog programs, at the American Diabetes Association 84th Annual Conference.

Zealand Pharma A/S announced presentations of clinical and non-clinical results for Zealand’s amylin analog ZP8396 at the Obesity Society Annual Meeting being held in Dallas, Texas from October 14-17, 2023.